Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proximicin C is a furan-based oligopeptide antibiotic and antitumor agent originally isolated from marine actinomycetes of the genus *Verrucosispora*. It is structurally characterized by the presence of the unusual amino acid 4-aminofuran-2-carboxylic acid and shares structural similarities with the DNA-binding agents distamycin and netropsin. Proximicin C exhibits significant cytotoxicity against various cancer cell lines, including gastric adenocarcinoma, glioblastoma (U-87 MG), and breast carcinoma (MDA-MD-231). Its mechanism of action involves binding to DNA and inducing the up-regulation of p53 and p21, leading to cell-cycle arrest at the G1/S transition and subsequent apoptosis. Research into proximicin C has demonstrated its potential as a synthetic target for the development of broad-utility anticancer drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proximicin C.